home / stock / bfra / bfra news

BFRA News and Press, Biofrontera AG From 02/24/21

Stock Information
Company Name: Biofrontera AG
Stock Symbol: BFRA
Market: NASDAQ
Menu
BFRA BFRA Quote BFRA Short BFRA News BFRA Articles BFRA Message Board
Get BFRA Alerts

News, Short Squeeze, Breakout and More Instantly...
BFRA - Biofrontera prices $8.9M public offering of ADS; shares down 8%

Biofrontera ([[BFRA]] -8.5%) prices U.S. underwritten public offering of 1,334,002 ADSs, at an offering price of $6.68/ADS; company expects to receive aggregate gross proceeds of ~$8.9M.Proceeds to be used to conduct clinical studies aimed at improving the market positioning of Biofrontera&#x...
BFRA - Sunesis Pharmaceuticals, Owens & Minor leads healthcare gainers; Rafael, Constellation Pharmaceuticals among major losers

Gainers: Sunesis Pharmaceuticals (SNSS) +38%, Owens & Minor (OMI) +32%, Salarius Pharmaceuticals (SLRX) +20%, Poseida Therapeutics (PSTX) +20%, PRA Health Sciences (PRAH) +19%.Losers: Rafael (RFL) -12%, Constellation Pharmaceuticals (CNST)...

BFRA - Biofrontera submits study report of pharmacokinetics study to FDA

Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the submission of an application to the U.S. Food and Drug Administration (FDA) to ame...

BFRA - Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares

NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES Leverkusen, Germany, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today announce...
BFRA - Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021

Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a change in the company's Management Board. Effective March 1...

BFRA - Biofrontera anticipates fiscal year sales of Euro30.3M, slightly lower from a year ago

Germany based biopharmaceutical company, Biofrontera ([[BFRA]] +0.1%) sees fiscal year 2020 sales of €30.3M - €30.6M, vs. €31.3M, a year ago, attributable to fall in US sales in particular was due to the development of the pandemic crisis situation. Ho...

BFRA - Biofrontera announces preliminary revenue figures for the full year 2020

Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020. Biofrontera Group's ...
BFRA - Cologne Higher Regional Court grants approval of capital increase

Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the Cologne Higher Regional Court has granted the release of the capital increase res...

BFRA - Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia

Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö, Sweden, today signed an exclusive license and supply agreement for the marketing of bot...

BFRA - Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds

Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00% qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E45...
Previous 10 Next 10